Piper Jaffray Companies cut shares of Bioverativ (NASDAQ:BIVV) from an overweight rating to a neutral rating in a research note released on Monday.

Several other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Bioverativ from a hold rating to a buy rating and set a $62.00 price target on the stock in a report on Monday, January 8th. Deutsche Bank set a $53.00 target price on Bioverativ and gave the stock a hold rating in a report on Monday, November 20th. Credit Suisse Group restated a neutral rating and set a $65.00 target price on shares of Bioverativ in a report on Thursday, January 18th. Morgan Stanley restated an underweight rating and set a $47.00 target price (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Finally, Royal Bank of Canada raised their target price on Bioverativ to $68.00 and gave the stock a market perform rating in a report on Thursday, January 18th. Twelve investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Bioverativ currently has an average rating of Hold and an average target price of $62.53.

Bioverativ (NASDAQ:BIVV) traded down $0.63 during trading on Monday, reaching $103.16. The company had a trading volume of 10,083,220 shares, compared to its average volume of 3,192,829. The company has a market capitalization of $11,160.00 and a PE ratio of 25.22. Bioverativ has a fifty-two week low of $40.99 and a fifty-two week high of $104.30.

Bioverativ (NASDAQ:BIVV) last posted its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.25. The business had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The business’s quarterly revenue was up 27.2% on a year-over-year basis. sell-side analysts anticipate that Bioverativ will post 2.69 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of BIVV. Quotient Investors LLC acquired a new stake in shares of Bioverativ during the third quarter worth about $420,000. Mutual of America Capital Management LLC acquired a new stake in shares of Bioverativ during the third quarter worth about $5,062,000. Meeder Asset Management Inc. acquired a new stake in shares of Bioverativ during the third quarter worth about $877,000. Rockefeller Financial Services Inc. acquired a new stake in shares of Bioverativ during the third quarter worth about $1,480,000. Finally, State Treasurer State of Michigan acquired a new stake in shares of Bioverativ during the third quarter worth about $2,323,000. Hedge funds and other institutional investors own 96.04% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/01/23/piper-jaffray-companies-lowers-bioverativ-bivv-to-neutral.html.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Analyst Recommendations for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.